e collaborating on ALN-RSV, but further development has slowed since Cubist opted-out of the collaboration after a mixed result in a phase 2 study. Alios (private) has an oral nucleoside analog (AL-8176) currently in a proof-of-concept study in adults, which could have data in the near term • Incide